Showing results (341-350 of 4,238) with videos related to
Sort By:
Pageof 424
Journal for Immunotherapy of Cancer|June 8, 2025
Hyperglycemia in patients treated with immune checkpoint inhibitors: key clinical challenges and multidisciplinary consensus recommendationsLinda Wu, Venessa Tsang, Roderick Clifton-Bligh, et al.Journal for Immunotherapy of Cancer|July 15, 2025
Disruption of cell-intrinsic PCSK9 enhances the antitumor efficacy of CD8+ T cellsBing Liu, Letong Cai, Yiwen Yan, et al.Journal for Immunotherapy of Cancer|July 15, 2025
Randomized phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small-cell lung cancer (NSCLC): Big Ten Cancer Research Consortium LUN16-081Greg Durm, Hirva Mamdani, Sandra Althouse, et al.Journal for Immunotherapy of Cancer|July 11, 2025
Shared epitopes create safety and efficacy concerns in several cancer vaccinesGuillaume Kellermann, Baharia Mograbi, Paul Hofman, et al.Journal for Immunotherapy of Cancer|May 30, 2025
Super-high tumor mutational burden predicts complete remission following immunotherapy: from Peto's paradox to druggable cancer hallmarkMing ZhengJournal for Immunotherapy of Cancer|June 23, 2025
Piezo1 deletion enhances cross-priming of CD8+ T cells by tumor-infiltrating CD11b+ dendritic cellsMelissa Bonner, David Askew, Vrishabhadev Sathish Kumar, et al.Journal for Immunotherapy of Cancer|June 23, 2025
Novel fusion superkine, IL-24S/IL-15, enhances immunotherapy of brain cancerAmit Kumar, Praveen Bhoopathi, Padmanabhan Mannangatti, et al.Journal for Immunotherapy of Cancer|June 23, 2025
Cancer immunotherapy clinical trials to support urgently needed access in low- and middle-income countries: a report from the SITC global access and impact committeeJennifer Dent, Micaella Jorge, Nora Sobrevilla, et al.Journal for Immunotherapy of Cancer|June 15, 2025
Commentary on "Targeted release of a bispecific fusion protein SIRPα/Siglec-10 by oncolytic adenovirus reinvigorates tumor-associated macrophages to improve therapeutic outcomes in solid tumors"Marc Lecoultre, Aya El HelaliJournal for Immunotherapy of Cancer|October 6, 2025
Macrophage NLRP3 activation and IL-1β release drive osimertinib-induced antitumor immunityHaiyang Yu, Xin Sun, Yan Li, et al.Pageof 424